Drug Discovery

#Antigen #Awards #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Winners of ‘The Best Covid-19 Responder’ announced

The Native Antigen Company has won ‘The Best Covid-19 Responder’ at the OBN 2020 Awards. The award recognises the Company’s contribution to the fight against Covid-19. The Native Antigen Company has utilised its expertise in developing high-quality reagents to play a major role in the global response to SARS-CoV-2. In… Read More

#News

#Automation / robotics #Bioscience #CRO #Drug delivery #Drug development

Video highlights reinvention of western blotting

Aurelia Bioscience, a Nottingham, UK based pre-clinical Contract Research Organisation (CRO) has produced a new video to explain the functioning of WES and JESS – two highly reproducible, capillary based, automated western blot instruments from ProteinSimple: Whilst traditional western blotting typically runs 10-20 samples in three to five… Read More

#News

#AstraZeneca #Biologics / Biotechnology #Clinical trials #Drug delivery #Drug development #Pharma

Chinese/Western partnership to promote indigenous drugs

Chinese biopharma companies are eyeing strategic collaborations with Western counterparts to leverage their networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the… Read More

#Market Reports #News #Trends & Analysis

#Biologics #Biopharmaceuticals #Drug delivery #Drug development #Events #Process analytical technology

Agilent completes the InfinityLab Bio LC portfolio

Agilent Technologies has launched three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release has been described by Agilent as central to its portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that integrate with Agilent OpenLab and MassHunter software, and… Read More

#News

#Biosciences #Drug delivery #Drug development #Drug discovery

Charnwood Group acquires Aurelia Bioscience

Aurelia Bioscience has announced that after ten years as a standalone biology contract research organisation, the company has been acquired by its collaborator Charnwood Molecular. Co-located in BioCity Nottingham, Aurelia Bioscience and Charnwood Molecular have previously jointly delivered research projects. This acquisition is said to allow both companies to formally… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Biden to invest US$3 bn to boost Covid-19 drug discovery

As part of the American Rescue Plan, the Biden Administration is investing more than US$3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the whole-of-government strategy to develop the next generation of Covid-19 treatments. Through collaboration within the US Department of Health and Human… Read More

#News #Trending News

#Covid-19 #Drug delivery #Drug development

Corticosteroids could treat Covid-19 complications in children

Corticosteroids may be an effective treatment for children who develop a rare but serious condition after Covid-19 infection. This is the finding of an international study of 614 children, published in the New England Journal of Medicine, led by Imperial College London. All children in the study developed a serious… Read More

#News

#Clinical trials #Drug development #Drug screening #Screening

Sygnature Discovery expands into early CMC development

Sygnature Discovery has announced the set-up of an Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials. With over £1 million… Read More

#News

#Drug development #Inflammatory Bowel Disease #Microbiology #Microbiome

Funding for new microbiome marker to aid treatment of IBD

Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an… Read More

#News

#Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Oncology

New oncology research and development collaboration

Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for… Read More

#News

#Drug development #Gene therapy #mRNA #Therapeutics

Evonik to develop new drug delivery platform for mRNA

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). Starting in June 2021, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license… Read More

#News

#CRISPR #Drug discovery #Target validation #Webinar

Join GSK for this exclusive CRISPR-Cas screen event

Navigating from target identification to validation can be a complex process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of spending vast amounts of money on clinical trials. CRISPR-Cas gene editing has made an impact in this space with forward… Read More

#News

#Biologics #Cell and gene therapy #Drug development

Yposkesi launches construction of its second commercial bioproduction site

Yposkesi, a Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapies, has announced the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat… Read More

#News

#Drug development #Pharma #Pharmatech

Assessing IDMP maturity as the data-driven future takes form

With the latest EU IDMP guidance now published, pharma companies must now measure their readiness for the new world, in which data-based regulatory submissions run parallel with, and will ultimately replace, single-use documents. Here, Adnan Jamil, a Senior Consultant at data-driven life sciences transformation specialist, Iperion, offers step-by-step advice to… Read More

#Exclusive Content #News

#Cell painting #Drug discovery #Genetics

PerkinElmer’s support creates world’s largest public cell painting dataset

PerkinElmer is providing its PhenoVue Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium. The consortium, spearheaded by the Broad Institute of MIT and Harvard and including leading pharmaceutical companies and non-profit research organisations, is focused on creating and sharing the world’s largest, public cell imaging… Read More

#News

#Bioscience #Drug development #Drug discovery

Taconic Biosciences launches TruIMPORT importation solution

Taconic Biosciences has launched a new solution, TruIMPORT, for importing genetically engineered models from China into academia vivarium without quarantine, in collaboration with Cyagen. Researchers at non-profit institutions play a critical role in drug discovery; however, outsourcing animal model generation can be cost prohibitive or a logistical challenge. Hurdles in… Read More

#News